AAD 2019—Secukinumab maintains PASI75 response in psoriasis


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Secukinumab maintained improvement in Psoriasis Activity and Severity Index (PASI) 75 (PASI75) scores in moderate-to-severe psoriasis, a 5-year phase 3 extension study showed.

Why this matters

  • Secukinumab, an IL-17A monoclonal antibody, produces a complete and long-lasting response in patients with psoriasis.
  • This study is the longest and largest to date to examine the long-term efficacy, safety, and tolerability of a biologic in psoriasis treatment.   

Key results

  • In patients receiving secukinumab, PASI responses were sustained until week 260:
    • PASI75/90/100 (85.1%/ 67.2%/ 37.8%).
    • PASI≤1 (46%).
    • Mean PASI score (2.2) in secukinumab 300 mg stay group.  
  • No new safety signals were reported for secukinumab.

Study design

  • Week 52 PASI75 responders from 2 pivotal trials were randomly assigned 2:1 to secukinumab (300 or 150 mg) or placebo every 4 weeks, until week 156 or relapse (as defined by >50% reduction in maximal PASI score from baseline).
  • Patients who relapsed on placebo received secukinumab.
  • At week 156, all patients received secukinumab (patients continued secukinumab 300 or 150 mg, or could opt to switch from 150 to 300 mg secukinumab).
  • Funding: Novartis, Inc.

Limitations

  • Open-label study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit